Switch to:
Also traded in: Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 23.14
TR's Cash-to-Debt is ranked higher than
74% of the 1576 Companies
in the Global Confectioners industry.

( Industry Median: 0.65 vs. TR: 23.14 )
Ranked among companies with meaningful Cash-to-Debt only.
TR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 12.56 Max: No Debt
Current: 23.14
Equity-to-Asset 0.77
TR's Equity-to-Asset is ranked higher than
83% of the 1540 Companies
in the Global Confectioners industry.

( Industry Median: 0.52 vs. TR: 0.77 )
Ranked among companies with meaningful Equity-to-Asset only.
TR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.7  Med: 0.78 Max: 0.83
Current: 0.77
0.7
0.83
Interest Coverage N/A
TR's Interest Coverage is ranked higher than
87% of the 1370 Companies
in the Global Confectioners industry.

( Industry Median: 19.63 vs. TR: N/A )
Ranked among companies with meaningful Interest Coverage only.
TR' s Interest Coverage Range Over the Past 10 Years
Min: 132.43  Med: 493.11 Max: 1198.45
Current: N/A
132.43
1198.45
Piotroski F-Score: 8
Altman Z-Score: 5.37
Beneish M-Score: -2.79
WACC vs ROIC
4.47%
11.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 17.73
TR's Operating Margin % is ranked higher than
86% of the 1561 Companies
in the Global Confectioners industry.

( Industry Median: 5.68 vs. TR: 17.73 )
Ranked among companies with meaningful Operating Margin % only.
TR' s Operating Margin % Range Over the Past 10 Years
Min: 10.89  Med: 13.37 Max: 17.73
Current: 17.73
10.89
17.73
Net Margin % 12.96
TR's Net Margin % is ranked higher than
85% of the 1565 Companies
in the Global Confectioners industry.

( Industry Median: 3.98 vs. TR: 12.96 )
Ranked among companies with meaningful Net Margin % only.
TR' s Net Margin % Range Over the Past 10 Years
Min: 7.82  Med: 10.58 Max: 12.96
Current: 12.96
7.82
12.96
ROE % 9.61
TR's ROE % is ranked higher than
56% of the 1523 Companies
in the Global Confectioners industry.

( Industry Median: 8.16 vs. TR: 9.61 )
Ranked among companies with meaningful ROE % only.
TR' s ROE % Range Over the Past 10 Years
Min: 6.09  Med: 8.25 Max: 9.58
Current: 9.61
6.09
9.58
ROA % 7.40
TR's ROA % is ranked higher than
72% of the 1600 Companies
in the Global Confectioners industry.

( Industry Median: 3.84 vs. TR: 7.40 )
Ranked among companies with meaningful ROA % only.
TR' s ROA % Range Over the Past 10 Years
Min: 4.77  Med: 6.48 Max: 7.38
Current: 7.4
4.77
7.38
ROC (Joel Greenblatt) % 39.63
TR's ROC (Joel Greenblatt) % is ranked higher than
83% of the 1587 Companies
in the Global Confectioners industry.

( Industry Median: 13.34 vs. TR: 39.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 22.29  Med: 28.17 Max: 41.84
Current: 39.63
22.29
41.84
3-Year Revenue Growth Rate 0.10
TR's 3-Year Revenue Growth Rate is ranked lower than
60% of the 1341 Companies
in the Global Confectioners industry.

( Industry Median: 2.50 vs. TR: 0.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.5  Med: 4.8 Max: 16.9
Current: 0.1
-0.5
16.9
3-Year EBITDA Growth Rate 10.00
TR's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 1162 Companies
in the Global Confectioners industry.

( Industry Median: 5.30 vs. TR: 10.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -42.3  Med: 7.7 Max: 85.1
Current: 10
-42.3
85.1
3-Year EPS without NRI Growth Rate 5.00
TR's 3-Year EPS without NRI Growth Rate is ranked lower than
51% of the 1041 Companies
in the Global Confectioners industry.

( Industry Median: 5.40 vs. TR: 5.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -43.8  Med: 6 Max: 140.3
Current: 5
-43.8
140.3
GuruFocus has detected 5 Warning Signs with Tootsie Roll Industries Inc $TR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TR's 10-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

TR Guru Trades in Q1 2016

Paul Tudor Jones 6,314 sh (New)
Chuck Royce 745,837 sh (+2.29%)
Mario Gabelli 1,302,085 sh (+0.32%)
Murray Stahl 15,506 sh (-18.91%)
Jim Simons 137,500 sh (-29.23%)
» More
Q2 2016

TR Guru Trades in Q2 2016

Joel Greenblatt 7,342 sh (New)
Chuck Royce 745,837 sh (unchged)
Paul Tudor Jones Sold Out
Mario Gabelli 1,277,211 sh (-1.91%)
Murray Stahl 12,238 sh (-21.08%)
Jim Simons 51,746 sh (-62.37%)
» More
Q3 2016

TR Guru Trades in Q3 2016

Chuck Royce 760,837 sh (+2.01%)
Joel Greenblatt Sold Out
Mario Gabelli 1,257,190 sh (-1.57%)
Murray Stahl 11,399 sh (-6.86%)
Jim Simons 28,801 sh (-44.34%)
» More
Q4 2016

TR Guru Trades in Q4 2016

Chuck Royce 890,022 sh (+16.98%)
Jim Simons Sold Out
Mario Gabelli 1,240,454 sh (-1.33%)
Murray Stahl 10,840 sh (-4.90%)
» More
» Details

Insider Trades

Latest Guru Trades with TR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Consumer Packaged Goods » Confectioners    NAICS: 311352    SIC: 2064
Compare:OTCPK:MGAAF, OTCPK:TGATF, OTCPK:PEFDF, OTCPK:KHKSF, OTCPK:RSGUF, OTCPK:GUAXF, NAS:RMCF, OTCPK:ATLT, OTCPK:PARF, OTCPK:BYCBF, OTCPK:COCXF, NYSE:HSY, NAS:MDLZ » details
Traded in other countries:TZ3.Germany, TROLB.USA,
Headquarter Location:USA
Tootsie Roll Industries Inc manufactures and sells confectionery products. Its manufacturing operations are located in the United States and Canada.

Tootsie Roll manufactures and sells candy products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, and Razzles. The company sells its products to wholesale distributors and directly to retail stores. Nearly a quarter of total sales are from products sold through Wal-Mart. Tootsie Roll's principal markets are in the United States, Canada, and Mexico. More than 90% of sales are to customers located in the United States.

Top Ranked Articles about Tootsie Roll Industries Inc

Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress

TORONTO, ONTARIO--(Marketwired - Jun 7, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 (SIRPaFc) immune checkpoint inhibitor program at the European Hematology Association 21st Annual Congress, to be held in Copenhagen from June 9-12. Details of Trillium's presentation are as follows: Presentation Type: Electronic Poster Abstract #: E1373 Title: The CD47-blocking Cancer Immunotherapeutic TTI-621 has Anti-Tumor Effects Across a Broad Range of Hematological Malignancies About Trillium Therapeutics Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin. It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory ("do not eat") signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic ("eat") signals. A Phase I clinical trial (NCT02663518) evaluating SIRPaFc (TTI-621) is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company's most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase. For more information visit: www.trilliumtherapeutics.com. Caution Regarding Forward-Looking Information This press release may contain forward-looking statements, which reflect Trillium's current expectation regarding future results, events or developments. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties are described in the company's ongoing quarterly and annual reporting. Except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.





Trillium Therapeutics Inc.
James Parsons
Chief Financial Officer
416-595-0627 x232
[email protected]
www.trilliumtherapeutics.com
Investor and Media Relations:
Canale Communications for Trillium Therapeutics
Mark Corbae
619-849-5375
[email protected]




Read more...
Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders

TORONTO, ONTARIO--(Marketwired - May 31, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the voting results from its Annual and Special Meeting of shareholders held on May 27, 2016. The results of the director elections were as follows:




Name
Votes

in Favour
% Votes

in Favour
Votes

Withheld
% Votes

Withheld


Mr. Luke Beshar
2,799,000
99.67
9,243
0.33


Dr. Henry Friesen
2,612,006
93.01
196,237
6.99


Dr. Robert Kirkman
2,482,475
88.40
325,768
11.60


Dr. Michael Moore
2,612,672
93.04
195,571
6.96


Dr. Thomas Reynolds
2,798,733
99.66
9,510
0.34


Dr. Niclas Stiernholm
2,798,553
99.65
9,690
0.35


Dr. Calvin Stiller
2,612,131
93.02
196,112
6.98



The shareholders of the Corporation also voted to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants as auditors of the Corporation for the ensuing year, and approved the Corporation's 2016 Stock Option Plan and By-Law Amendment. About Trillium Therapeutics Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin. It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory ("do not eat") signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic ("eat") signals. A Phase I clinical trial (NCT02663518) evaluating SIRPaFc (TTI-621) is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company's most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase. For more information visit: www.trilliumtherapeutics.com Caution Regarding Forward-Looking Information This press release may contain forward-looking statements, which reflect Trillium's current expectation regarding future results, events or developments. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties are described in the company's ongoing quarterly and annual reporting. Except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.





Trillium Therapeutics Inc.
James Parsons
Chief Financial Officer
416-595-0627 x232
[email protected]
www.trilliumtherapeutics.com
Investor and Media Relations:
Mark Corbae
Canale Communications for Trillium Therapeutics
619-849-5375
[email protected]




Read more...
Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2016 ASCO Annual Meeting

TORONTO, ONTARIO--(Marketwired - May 18, 2016) - Trillium Therapeutics Inc. (TSX:TR) (NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 (SIRPaFc) immune checkpoint inhibitor program at the Trials in Progress Session of the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago from June 3-7. Details of Trillium's ASCO presentation are as follows:


Presentation Type: Poster


Abstract #: TPS7585


Title: A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory hematologic malignancies


Presenter: Stephen Maxted Ansell, M.D., Ph.D., Division of Hematology, Mayo Clinic


Track: Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia


Time/Location: Monday, June 6, 8-11:30 a.m. in Hall A, Poster Board #134b



About Trillium Therapeutics Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin. It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory ("do not eat") signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic ("eat") signals. A Phase I clinical trial (NCT02663518) evaluating SIRPaFc (TTI-621) is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company's most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase. For more information visit: www.trilliumtherapeutics.com Caution Regarding Forward-Looking Information This press release may contain forward-looking statements, which reflect Trillium's current expectation regarding future results, events or developments. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties are described in the company's ongoing quarterly and annual reporting. Except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.





Trillium Therapeutics Inc.
James Parsons
Chief Financial Officer
416-595-0627 x232
[email protected]
www.trilliumtherapeutics.com
Investor and Media Relations:
Mark Corbae
Canale Communications for Trillium Therapeutics
619-849-5375
[email protected]




Read more...
Trillium Reports First Quarter 2016 Financial Results

TTI-621 Phase I clinical trial progressing according to plans Completed acquisition and integration of Fluorinov Cash amounted to $65.8 million as of March 31, 2016

TORONTO, ONTARIO--(Marketwired - May 13, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three months ended March 31, 2016. "We made significant progress during the first quarter of 2016, positioning our oncology pipeline for long-term growth. Firstly, we advanced our lead CD47 clinical program on schedule, and secondly, we acquired Fluorinov, a preclinical company with a proprietary fluorine-based chemistry platform," said Dr. Niclas Stiernholm, president and chief executive officer of Trillium. "We are intensifying our internal research efforts on the biology of the CD47 pathway in order to understand how to best combine CD47 blockade with other therapies, and to elucidate the potential advantages of using a SIRPaFc fusion protein compared to a CD47-specific antibody. Additionally, key development activities related to the Fluorinov acquisition, involving several of its preclinical programs, are now underway." Corporate Update

The Phase I dose escalation clinical trial treating patients with advanced hematologic malignancies with TTI-621, an IgG1 SIRPaFc fusion protein targeting CD47, is progressing according to established timelines and an update on the trial is planned for the end of the year.



At the AACR 2016 Annual Meeting in April, Trillium presented data showing that TTI-621 promotes phagocytosis of lymphoma cells by diverse types of macrophages, including M2 macrophages, which are often implicated in tumor progression.



Following the acquisition of Fluorinov Pharma in January 2016, the company has quickly integrated its staff and operations. Preclinical development plans are currently being finalized.



Trillium has completed its relocation to a larger research and development facility and continues to grow key staff, with specific emphasis on the clinical and regulatory areas. The company has also added external resources in the form of additional legal and intellectual property support, as well as assistance with investor relations and corporate communications.

First Quarter 2016 Financial Results

(Amounts in Canadian dollars) As of March 31, 2016, Trillium had cash of $65.8 million. During the first quarter, the company used $9.5 million of cash for the acquisition of Fluorinov; $6.0 million for operations; recorded a net foreign exchange loss on cash of $3.6 million; and used $1.8 million for capital purchases related to its new office and laboratory facility. Net loss for the three months ended March 31, 2016 of $7.2 million compared to a loss of $4.7 million for the three months ended March 31, 2015. The net loss was higher due mainly to a net foreign currency loss of $3.6 million from holding US denominated cash with a weakening US dollar, amortization of $0.7 million on Fluorinov intangible assets and higher research and development spending. This was partially offset by the recognition of a deferred tax recovery in relation to the acquisition of Fluorinov of $3.7 million. About Trillium Therapeutics Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The Company's lead program, SIRPaFc, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin. It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory ("do not eat") signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic ("eat") signals. A Phase I clinical trial (NCT02663518) evaluating SIRPaFc (TTI-621) is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the Company's most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase. For more information visit: www.trilliumtherapeutics.com Caution Regarding Forward-Looking Information This press release may contain forward-looking statements, which reflect Trillium's current expectation regarding future results, events or developments, including our belief that TTI-621 promotes the phagocytosis of lymphoma cells by diverse types of macrophages. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties are described in the company's ongoing quarterly and annual reporting. Except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.





James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
416-595-0627 x232
[email protected]
www.trilliumtherapeutics.com
Mark Corbae
Canale Communications for Trillium Therapeutics
619-849-5375
[email protected]




Read more...

Ratios

vs
industry
vs
history
PE Ratio 35.95
TR's PE Ratio is ranked lower than
77% of the 1258 Companies
in the Global Confectioners industry.

( Industry Median: 20.28 vs. TR: 35.95 )
Ranked among companies with meaningful PE Ratio only.
TR' s PE Ratio Range Over the Past 10 Years
Min: 19.08  Med: 30.38 Max: 39.95
Current: 35.95
19.08
39.95
PE Ratio without NRI 35.95
TR's PE Ratio without NRI is ranked lower than
77% of the 1252 Companies
in the Global Confectioners industry.

( Industry Median: 20.28 vs. TR: 35.95 )
Ranked among companies with meaningful PE Ratio without NRI only.
TR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 19.12  Med: 30.25 Max: 39.6
Current: 35.95
19.12
39.6
Price-to-Owner-Earnings 29.26
TR's Price-to-Owner-Earnings is ranked lower than
66% of the 693 Companies
in the Global Confectioners industry.

( Industry Median: 20.79 vs. TR: 29.26 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 17.63  Med: 27.32 Max: 51.23
Current: 29.26
17.63
51.23
PB Ratio 2.08
TR's PB Ratio is ranked lower than
56% of the 1512 Companies
in the Global Confectioners industry.

( Industry Median: 1.75 vs. TR: 2.08 )
Ranked among companies with meaningful PB Ratio only.
TR' s PB Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.77 Max: 2.82
Current: 2.08
1.19
2.82
PS Ratio 4.65
TR's PS Ratio is ranked lower than
86% of the 1516 Companies
in the Global Confectioners industry.

( Industry Median: 1.07 vs. TR: 4.65 )
Ranked among companies with meaningful PS Ratio only.
TR' s PS Ratio Range Over the Past 10 Years
Min: 2.22  Med: 3.16 Max: 4.9
Current: 4.65
2.22
4.9
Price-to-Free-Cash-Flow 29.35
TR's Price-to-Free-Cash-Flow is ranked lower than
68% of the 600 Companies
in the Global Confectioners industry.

( Industry Median: 18.92 vs. TR: 29.35 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 15.73  Med: 26.06 Max: 109.77
Current: 29.35
15.73
109.77
Price-to-Operating-Cash-Flow 24.56
TR's Price-to-Operating-Cash-Flow is ranked lower than
78% of the 841 Companies
in the Global Confectioners industry.

( Industry Median: 12.31 vs. TR: 24.56 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 14.14  Med: 20.56 Max: 32.51
Current: 24.56
14.14
32.51
EV-to-EBIT 12.64
TR's EV-to-EBIT is ranked higher than
67% of the 1680 Companies
in the Global Confectioners industry.

( Industry Median: 16.43 vs. TR: 12.64 )
Ranked among companies with meaningful EV-to-EBIT only.
TR' s EV-to-EBIT Range Over the Past 10 Years
Min: 12.5  Med: 21 Max: 27
Current: 12.64
12.5
27
EV-to-EBITDA 10.53
TR's EV-to-EBITDA is ranked higher than
61% of the 1719 Companies
in the Global Confectioners industry.

( Industry Median: 12.42 vs. TR: 10.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
TR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.9  Med: 16.5 Max: 21.3
Current: 10.53
10.9
21.3
PEG Ratio 3.79
TR's PEG Ratio is ranked lower than
70% of the 577 Companies
in the Global Confectioners industry.

( Industry Median: 2.04 vs. TR: 3.79 )
Ranked among companies with meaningful PEG Ratio only.
TR' s PEG Ratio Range Over the Past 10 Years
Min: 0.75  Med: 3.61 Max: 62.27
Current: 3.79
0.75
62.27
Shiller PE Ratio 43.63
TR's Shiller PE Ratio is ranked lower than
74% of the 264 Companies
in the Global Confectioners industry.

( Industry Median: 28.51 vs. TR: 43.63 )
Ranked among companies with meaningful Shiller PE Ratio only.
TR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 16.56  Med: 24.81 Max: 45.7
Current: 43.63
16.56
45.7
Current Ratio 4.71
TR's Current Ratio is ranked higher than
90% of the 1427 Companies
in the Global Confectioners industry.

( Industry Median: 1.60 vs. TR: 4.71 )
Ranked among companies with meaningful Current Ratio only.
TR' s Current Ratio Range Over the Past 10 Years
Min: 1.38  Med: 3.82 Max: 5.76
Current: 4.71
1.38
5.76
Quick Ratio 3.80
TR's Quick Ratio is ranked higher than
90% of the 1427 Companies
in the Global Confectioners industry.

( Industry Median: 1.08 vs. TR: 3.80 )
Ranked among companies with meaningful Quick Ratio only.
TR' s Quick Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.92 Max: 4.66
Current: 3.8
0.89
4.66
Days Inventory 78.90
TR's Days Inventory is ranked lower than
60% of the 1460 Companies
in the Global Confectioners industry.

( Industry Median: 63.56 vs. TR: 78.90 )
Ranked among companies with meaningful Days Inventory only.
TR' s Days Inventory Range Over the Past 10 Years
Min: 60.13  Med: 65.99 Max: 70.99
Current: 78.9
60.13
70.99
Days Sales Outstanding 30.09
TR's Days Sales Outstanding is ranked higher than
62% of the 1148 Companies
in the Global Confectioners industry.

( Industry Median: 38.13 vs. TR: 30.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
TR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.97  Med: 27.69 Max: 34.47
Current: 30.09
22.97
34.47
Days Payable 11.72
TR's Days Payable is ranked lower than
90% of the 1023 Companies
in the Global Confectioners industry.

( Industry Median: 45.59 vs. TR: 11.72 )
Ranked among companies with meaningful Days Payable only.
TR' s Days Payable Range Over the Past 10 Years
Min: 8.9  Med: 11.19 Max: 15.16
Current: 11.72
8.9
15.16

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.93
TR's Dividend Yield % is ranked higher than
79% of the 1628 Companies
in the Global Confectioners industry.

( Industry Median: 1.81 vs. TR: 0.93 )
Ranked among companies with meaningful Dividend Yield % only.
TR' s Dividend Yield % Range Over the Past 10 Years
Min: 0.02  Med: 1.05 Max: 1.44
Current: 0.93
0.02
1.44
Dividend Payout Ratio 0.33
TR's Dividend Payout Ratio is ranked higher than
56% of the 986 Companies
in the Global Confectioners industry.

( Industry Median: 0.36 vs. TR: 0.33 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TR' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0  Med: 0.33 Max: 0.42
Current: 0.33
0
0.42
3-Year Dividend Growth Rate 6.90
TR's 3-Year Dividend Growth Rate is ranked higher than
58% of the 677 Companies
in the Global Confectioners industry.

( Industry Median: 4.00 vs. TR: 6.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TR' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 406.6
Current: 6.9
0
406.6
Forward Dividend Yield % 0.93
TR's Forward Dividend Yield % is ranked lower than
82% of the 1557 Companies
in the Global Confectioners industry.

( Industry Median: 1.93 vs. TR: 0.93 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.20
TR's 5-Year Yield-on-Cost % is ranked higher than
78% of the 2022 Companies
in the Global Confectioners industry.

( Industry Median: 2.27 vs. TR: 1.20 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.03  Med: 1.37 Max: 1.87
Current: 1.2
0.03
1.87
3-Year Average Share Buyback Ratio 2.30
TR's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 698 Companies
in the Global Confectioners industry.

( Industry Median: -1.90 vs. TR: 2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.5  Med: 1.5 Max: 15.2
Current: 2.3
-16.5
15.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 16.27
TR's Price-to-Net-Current-Asset-Value is ranked lower than
78% of the 659 Companies
in the Global Confectioners industry.

( Industry Median: 6.36 vs. TR: 16.27 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 7.4  Med: 16.1 Max: 2236
Current: 16.27
7.4
2236
Price-to-Tangible-Book 3.19
TR's Price-to-Tangible-Book is ranked lower than
67% of the 1418 Companies
in the Global Confectioners industry.

( Industry Median: 1.91 vs. TR: 3.19 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.08  Med: 4.27 Max: 6.54
Current: 3.19
2.08
6.54
Price-to-Intrinsic-Value-Projected-FCF 1.74
TR's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
54% of the 659 Companies
in the Global Confectioners industry.

( Industry Median: 1.57 vs. TR: 1.74 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.32  Med: 1.62 Max: 4.12
Current: 1.74
1.32
4.12
Price-to-Median-PS-Value 1.47
TR's Price-to-Median-PS-Value is ranked lower than
69% of the 1320 Companies
in the Global Confectioners industry.

( Industry Median: 1.15 vs. TR: 1.47 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.58  Med: 1.04 Max: 1.6
Current: 1.47
0.58
1.6
Price-to-Peter-Lynch-Fair-Value 3.62
TR's Price-to-Peter-Lynch-Fair-Value is ranked lower than
88% of the 290 Companies
in the Global Confectioners industry.

( Industry Median: 1.64 vs. TR: 3.62 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
TR' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.18  Med: 2.21 Max: 5.69
Current: 3.62
1.18
5.69
Price-to-Graham-Number 2.26
TR's Price-to-Graham-Number is ranked lower than
73% of the 997 Companies
in the Global Confectioners industry.

( Industry Median: 1.42 vs. TR: 2.26 )
Ranked among companies with meaningful Price-to-Graham-Number only.
TR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.69  Med: 2.27 Max: 5.4
Current: 2.26
1.69
5.4
Earnings Yield (Greenblatt) % 7.91
TR's Earnings Yield (Greenblatt) % is ranked higher than
71% of the 1947 Companies
in the Global Confectioners industry.

( Industry Median: 5.41 vs. TR: 7.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.7  Med: 4.8 Max: 8
Current: 7.91
3.7
8
Forward Rate of Return (Yacktman) % 13.62
TR's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 771 Companies
in the Global Confectioners industry.

( Industry Median: 5.68 vs. TR: 13.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -5.8  Med: 9.2 Max: 39.5
Current: 13.62
-5.8
39.5

More Statistics

Revenue (TTM) (Mil) $521.1
EPS (TTM) $ 1.05
Beta0.38
Short Percentage of Float23.96%
52-Week Range $32.88 - 40.44
Shares Outstanding (Mil)37.96
» More Articles for TR

Headlines

Articles On GuruFocus.com
Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 a Jun 07 2016 
Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders May 31 2016 
Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 a May 18 2016 
Trillium Reports First Quarter 2016 Financial Results May 13 2016 
Trillium to Provide Update on CD47 Program at the 2016 American Association for Cancer Research Annu Apr 14 2016 
Trillium to Present at the 2016 Annual Needham Health Care Conference Apr 12 2016 
Trillium Announces a $3.4 Million Government Co-Funded Translational Research Program Mar 10 2016 
Trillium Reports 2015 Financial and Operating Results Mar 09 2016 
Trillium to Present at the Cowen and Company 36th Annual Health Care Conference Mar 08 2016 
Trillium Therapeutics Doses First Patient With TTI-621, a Novel Immune Checkpoint Inhibitor Targetin Feb 03 2016 

More From Other Websites
Tootsie Roll Industries, Inc. breached its 50 day moving average in a Bullish Manner : TR-US : April... Apr 10 2017
ETFs with exposure to Tootsie Roll Industries, Inc. : April 7, 2017 Apr 07 2017
Tootsie Roll Industries, Inc. : TR-US: Dividend Analysis : March 07th, 2017 (record date) : By the... Apr 03 2017
3 Dividend Champions We Refuse to Buy Mar 27 2017
Tootsie Roll Industries, Inc. breached its 50 day moving average in a Bearish Manner : TR-US : March... Mar 27 2017
Tootsie Roll Industries, Inc. :TR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017 Mar 02 2017
Go Long Tootsie Roll, Short Twinkies Mar 01 2017
Tootsie Roll posts 4Q profit Feb 09 2017
Tootsie Roll Industries, Inc. : TR-US: Dividend Analysis : December 19th, 2016 (record date) : By... Feb 06 2017
Tootsie Roll Industries, Inc. – Value Analysis (NYSE:TR) : January 11, 2017 Jan 11 2017
Tootsie Roll Industries, Inc. breached its 50 day moving average in a Bearish Manner : TR-US :... Jan 10 2017
ETFs with exposure to Tootsie Roll Industries, Inc. : January 9, 2017 Jan 09 2017
How Blockchain Could Help Strengthen Developing Nations Dec 27 2016
ETFs with exposure to Tootsie Roll Industries, Inc. : December 21, 2016 Dec 21 2016
Insider Buying Stays Red-Hot as Trump Rally Rolls On: Wendy’s, Medicines Company, Transdigm and... Dec 11 2016
Tootsie Roll Industries, Inc. (TR): Are Hedge Funds Right About This Stock? Dec 08 2016
Tootsie Roll Industries, Inc. :TR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 16, 2016 Nov 16 2016
ETF’s with exposure to Tootsie Roll Industries, Inc. : November 11, 2016 Nov 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)